Clinical Trials

The Heart Cells Foundation, at Barts Health NHS Trust, is funding the pioneering research and development of a revolutionary and potentially life-saving treatment that uses a patient’s own adult stem cells to repair the heart. Helping those with heart disease, whether they have suffered a heart attack or have developed a weak heart for other reasons.  Planning for Phase 3 of the Trials has now begun, alongside the opening of the Compassionate Treatment Centre.

The Trials

REGENERATE-AMI determined for the first time that it is possible to treat patients with cell therapy within 24 hours of suffering a heart attack. The trial showed that the therapy was safe and helped the heart recover. The results have been published in medical literature.

REGENERATE-DCM treated patients with a type of heart failure called dilated cardiomyopathy. The patients treated with cell therapy showed significant improvements in cardiac function, exercise capacity, quality of life, heart failure symptoms (NYHA class) and biochemical markers of heart failure (NT pro-BNP). The results have been published in medical literature.

REGENERATE-IHD treated patients suffering from ischaemic heart failure. The patients treated with cell therapy showed improvements in cardiac function, heart failure symptoms (NYHA class), quality of life scores and biochemical markers of heart failure (NT pro-BNP). The results have been published in medical literature.

BAMI took place across Europe and, to date, was the largest clinical trial of cell therapy to treat heart attacks. It has been seen as one of the most important contemporary studies in this field; with implications relevant to future trials involving patients with heart attacks, as well as studies involving cell therapy.  The results have been published in medical literature.